Le paludisme peut-il entraîner des complications graves ?
Oui, le paludisme peut causer des complications comme l'anémie sévère et le coma.
PaludismeComplications
#3
Comment gérer les complications transfusionnelles ?
La gestion inclut l'arrêt de la transfusion et le traitement des symptômes.
Réactions transfusionnellesTraitement médical
#4
Les complications sont-elles fréquentes avec le système Duffy ?
Les complications sont rares mais peuvent survenir en cas d'incompatibilité.
Système DuffyComplications médicales
#5
Quelles sont les conséquences d'une infection par le paludisme ?
Les conséquences incluent des défaillances organiques et des troubles neurologiques.
PaludismeConséquences
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour le paludisme ?
Les facteurs incluent vivre dans des zones endémiques et ne pas utiliser de protection.
PaludismeFacteurs de risque
#2
Les groupes sanguins rares sont-ils à risque ?
Oui, les groupes sanguins rares peuvent avoir un risque accru d'incompatibilité.
Groupes sanguinsRisque transfusionnel
#3
Les antécédents transfusionnels augmentent-ils le risque ?
Oui, des antécédents transfusionnels peuvent augmenter le risque de réactions.
Antécédents médicauxRéactions transfusionnelles
#4
Les femmes enceintes sont-elles à risque avec Duffy ?
Oui, les femmes enceintes peuvent avoir des complications liées au système Duffy.
GrossesseSystème Duffy
#5
Les voyageurs sont-ils à risque de paludisme ?
Oui, les voyageurs vers des zones à risque doivent prendre des précautions.
VoyagePaludisme
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Système Duffy : Questions médicales les plus fréquentes",
"headline": "Système Duffy : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Système Duffy : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-28",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Système Duffy"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes de groupe sanguin",
"url": "https://questionsmedicales.fr/mesh/D001789",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes de groupe sanguin",
"code": {
"@type": "MedicalCode",
"code": "D001789",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.705.230"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Système Duffy",
"alternateName": "Duffy Blood-Group System",
"code": {
"@type": "MedicalCode",
"code": "D004375",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Eugenia Lo",
"url": "https://questionsmedicales.fr/author/Eugenia%20Lo",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA."
}
},
{
"@type": "Person",
"name": "Delenasaw Yewhalaw",
"url": "https://questionsmedicales.fr/author/Delenasaw%20Yewhalaw",
"affiliation": {
"@type": "Organization",
"name": "Tropical and Infectious Diseases Research Center, Jimma University, Jimma, Ethiopia."
}
},
{
"@type": "Person",
"name": "Martin L Olsson",
"url": "https://questionsmedicales.fr/author/Martin%20L%20Olsson",
"affiliation": {
"@type": "Organization",
"name": "Medical Director of the Nordic Reference Laboratory for Genomic Blood Group Typing and Senior Consultant at the Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne; Professor of Transfusion Medicine at the Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, and Vice-Dean at the Faculty of Medicine, Lund University."
}
},
{
"@type": "Person",
"name": "Rei Rama",
"url": "https://questionsmedicales.fr/author/Rei%20Rama",
"affiliation": {
"@type": "Organization",
"name": "University of North Carolina at Charlotte."
}
},
{
"@type": "Person",
"name": "Lilian Castilho",
"url": "https://questionsmedicales.fr/author/Lilian%20Castilho",
"affiliation": {
"@type": "Organization",
"name": "Professor and Researcher, Hemocentro Campinas, University of Campinas, Rua Carlos Chagas."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prenatal diagnosis and genetic etiology analysis of talipes equinovarus by chromosomal microarray analysis.",
"datePublished": "2023-11-20",
"url": "https://questionsmedicales.fr/article/37986075",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12920-023-01733-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessing the Differential Methylation Analysis Quality for Microarray and NGS Platforms.",
"datePublished": "2023-05-11",
"url": "https://questionsmedicales.fr/article/37239934",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24108591"
}
},
{
"@type": "ScholarlyArticle",
"name": "Chromosomal microarray analysis in pregnancy loss: Is it time for a consensus approach?",
"datePublished": "2022-10-06",
"url": "https://questionsmedicales.fr/article/36176068",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pd.6244"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Multicenter Analysis of Abnormal Chromosomal Microarray Findings in Congenital Heart Disease.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37681527",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.029340"
}
},
{
"@type": "ScholarlyArticle",
"name": "Whole genome sequencing vs chromosomal microarray analysis in prenatal diagnosis.",
"datePublished": "2023-03-11",
"url": "https://questionsmedicales.fr/article/36907537",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajog.2023.03.005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isoantigènes",
"item": "https://questionsmedicales.fr/mesh/D007519"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigènes de groupe sanguin",
"item": "https://questionsmedicales.fr/mesh/D001789"
},
{
"@type": "ListItem",
"position": 6,
"name": "Système Duffy",
"item": "https://questionsmedicales.fr/mesh/D004375"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Système Duffy - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Système Duffy",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Système Duffy",
"description": "Comment déterminer le groupe sanguin Duffy ?\nQuels tests sont utilisés pour le système Duffy ?\nLe groupe Duffy peut-il changer ?\nQuels sont les types de groupes Duffy ?\nComment le groupe Duffy affecte-t-il les transfusions ?",
"url": "https://questionsmedicales.fr/mesh/D004375?mesh_terms=Microarray+Analysis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Système Duffy",
"description": "Quels symptômes sont liés à l'incompatibilité Duffy ?\nL'absence d'antigène Duffy cause-t-elle des symptômes ?\nLes infections sont-elles liées au système Duffy ?\nComment le système Duffy affecte-t-il la santé ?\nY a-t-il des symptômes spécifiques au paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375?mesh_terms=Microarray+Analysis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Système Duffy",
"description": "Comment prévenir les incompatibilités Duffy ?\nY a-t-il des mesures préventives pour le paludisme ?\nLes donneurs de sang doivent-ils être testés ?\nComment sensibiliser sur le système Duffy ?\nLes vaccinations aident-elles contre le paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375?mesh_terms=Microarray+Analysis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Système Duffy",
"description": "Comment traiter une réaction transfusionnelle Duffy ?\nY a-t-il un traitement pour l'absence d'antigène Duffy ?\nComment prévenir les réactions transfusionnelles ?\nLe paludisme a-t-il un traitement spécifique ?\nLes transfusions peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D004375?mesh_terms=Microarray+Analysis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Système Duffy",
"description": "Quelles complications peuvent survenir après une transfusion ?\nLe paludisme peut-il entraîner des complications graves ?\nComment gérer les complications transfusionnelles ?\nLes complications sont-elles fréquentes avec le système Duffy ?\nQuelles sont les conséquences d'une infection par le paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375?mesh_terms=Microarray+Analysis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Système Duffy",
"description": "Quels sont les facteurs de risque pour le paludisme ?\nLes groupes sanguins rares sont-ils à risque ?\nLes antécédents transfusionnels augmentent-ils le risque ?\nLes femmes enceintes sont-elles à risque avec Duffy ?\nLes voyageurs sont-ils à risque de paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375?mesh_terms=Microarray+Analysis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment déterminer le groupe sanguin Duffy ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le groupe sanguin Duffy est déterminé par des tests sérologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le système Duffy ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'agglutination et des tests d'anticorps sont utilisés pour le système Duffy."
}
},
{
"@type": "Question",
"name": "Le groupe Duffy peut-il changer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le groupe sanguin Duffy est déterminé génétiquement et ne change pas."
}
},
{
"@type": "Question",
"name": "Quels sont les types de groupes Duffy ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux groupes Duffy sont Fya et Fyb, avec des variations possibles."
}
},
{
"@type": "Question",
"name": "Comment le groupe Duffy affecte-t-il les transfusions ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une incompatibilité Duffy peut entraîner des réactions transfusionnelles."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à l'incompatibilité Duffy ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des réactions allergiques, fièvre et anémie."
}
},
{
"@type": "Question",
"name": "L'absence d'antigène Duffy cause-t-elle des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'absence d'antigène Duffy n'entraîne généralement pas de symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles liées au système Duffy ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections, comme le paludisme, sont influencées par le système Duffy."
}
},
{
"@type": "Question",
"name": "Comment le système Duffy affecte-t-il la santé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il influence la susceptibilité aux infections et les réactions transfusionnelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au paludisme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes du paludisme incluent fièvre, frissons, et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "Comment prévenir les incompatibilités Duffy ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des tests sanguins avant toute transfusion."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour le paludisme ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation de moustiquaires et de répulsifs aide à prévenir le paludisme."
}
},
{
"@type": "Question",
"name": "Les donneurs de sang doivent-ils être testés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, tous les donneurs de sang doivent être testés pour les groupes sanguins."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser sur le système Duffy ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information peuvent sensibiliser sur l'importance des tests sanguins."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles contre le paludisme ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent réduire le risque d'infection par le paludisme."
}
},
{
"@type": "Question",
"name": "Comment traiter une réaction transfusionnelle Duffy ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'arrêt de la transfusion et la gestion des symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un traitement pour l'absence d'antigène Duffy ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de traitement nécessaire pour l'absence d'antigène Duffy."
}
},
{
"@type": "Question",
"name": "Comment prévenir les réactions transfusionnelles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des tests de compatibilité rigoureux avant transfusion."
}
},
{
"@type": "Question",
"name": "Le paludisme a-t-il un traitement spécifique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le paludisme est traité avec des antipaludiques comme la chloroquine."
}
},
{
"@type": "Question",
"name": "Les transfusions peuvent-elles être évitées ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des alternatives comme les médicaments ou les transfusions autologues peuvent être utilisées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une transfusion ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réactions allergiques, hémolyse et choc transfusionnel."
}
},
{
"@type": "Question",
"name": "Le paludisme peut-il entraîner des complications graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le paludisme peut causer des complications comme l'anémie sévère et le coma."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications transfusionnelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt de la transfusion et le traitement des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec le système Duffy ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir en cas d'incompatibilité."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une infection par le paludisme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent des défaillances organiques et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le paludisme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent vivre dans des zones endémiques et ne pas utiliser de protection."
}
},
{
"@type": "Question",
"name": "Les groupes sanguins rares sont-ils à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les groupes sanguins rares peuvent avoir un risque accru d'incompatibilité."
}
},
{
"@type": "Question",
"name": "Les antécédents transfusionnels augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents transfusionnels peuvent augmenter le risque de réactions."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes sont-elles à risque avec Duffy ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes peuvent avoir des complications liées au système Duffy."
}
},
{
"@type": "Question",
"name": "Les voyageurs sont-ils à risque de paludisme ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs vers des zones à risque doivent prendre des précautions."
}
}
]
}
]
}
Medical Director of the Nordic Reference Laboratory for Genomic Blood Group Typing and Senior Consultant at the Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne; Professor of Transfusion Medicine at the Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, and Vice-Dean at the Faculty of Medicine, Lund University.
Immunohematology, Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Office for Medical Services , Akutgatan 8, SE-22185, Lund , Sweden.
Department of Pathology, Hale Building for Transformative Medicine, Brigham and Women's Hospital, Rm 8002L, 60 Fenwood Rd, Boston, MA, 02115, USA. wlane@bwh.harvard.edu.
Harvard Medical School, Boston, MA, USA. wlane@bwh.harvard.edu.
Associate Professor, Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, and Technical Director of Immunohematology Laboratories, Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden.
With the advancement of molecular technology, fetal talipes equinovarus (TE) is believed to be not only associated with chromosome aneuploidy, but also related to chromosomal microdeletion and microdu...
This retrospectively study included 131 fetuses with TE identified by ultrasonography. Conventional karyotyping and SNP array analysis were performed for all the subjects. They were divided into isola...
Among the total of 131 fetuses, karyotype analysis found 12(9.2%) abnormal results, while SNP array found 27 (20.6%) cases. Trisomy 18 was detected most frequently among abnormal karyotypes. The detec...
Fetal TE is related to chromosomal microdeletion or microduplication. Prenatal diagnosis is recommended for fetuses with TE, and CMA testing is preferred. CMA can improve the detection rate of chromos...
Differential methylation (DM) is actively recruited in different types of fundamental and translational studies. Currently, microarray- and NGS-based approaches for methylation analysis are the most w...
To investigate the efficacy and outcomes of chromosomal microarray (CMA) in the cytogenomic evaluation of products of conception (POC)....
Over a 42-month period, 323 POC samples were tested by CMA. Results were assessed using variables including phenotype, gestational age, results from orthogonal testing, and follow-up parental analysis...
CMA identified cytogenetic abnormalities in 47.4% of first trimester losses and 10.9% of second and third trimester losses. Chromosomal microarray results specifically from 5 to 7-week losses showed s...
Our findings of specific types of genetic abnormalities and the respective frequencies by gestational age closely align with those of published karyotype studies, supporting the use of routine CMA tes...
Background Chromosomal microarray analysis (CMA) provides an opportunity to understand genetic causes of congenital heart disease (CHD). The methods for describing cardiac phenotypes in patients with ...
Emerging studies suggest that whole genome sequencing provides additional diagnostic yield of genomic variants when compared with chromosomal microarray analysis in the etiologic diagnosis of infants ...
This study aimed to evaluate the accuracy, efficacy, and incremental yield of whole genome sequencing in comparison with chromosomal microarray analysis for routine prenatal diagnosis....
In this prospective study, a total of 185 unselected singleton fetuses with ultrasound-detected structural anomalies were enrolled. In parallel, each sample was subjected to whole genome sequencing an...
Overall, genetic diagnoses using whole genome sequencing were obtained for 28 (15.1%) cases. Whole genome sequencing not only detected all these aneuploidies and copy number variations in the 20 (10.8...
Compared with chromosomal microarray analysis, whole genome sequencing increased the additional detection rate by 5.9% (11/185). Using whole genome sequencing, we detected not only aneuploidies and co...
The current study aimed to compare the characteristics of chromosome abnormalities detected by conventional G-banding karyotyping, chromosome microarray analysis (CMA), or fluorescence in situ hybridi...
From March 2019 to March 2021, 3710 amniocentesis samples were retrospectively collected from women who accepted prenatal diagnosis at 16 to 22 + 6 weeks of pregnancy. The pregnant women underwent kar...
In total, 3710 G-banding karyotype results and CMA results from invasive prenatal diagnosis were collected. Of these, 201 (5.41%) fetuses with an abnormal karyotype were observed. The CMA analysis sho...
Conventional G-banding karyotyping and CMA have their own advantages and limitations. A combination of karyotype analysis and CMA can increase the detection rate of chromosome abnormalities and make u...
Chromosomal microarray analysis (CMA) is considered a first-tier test for patients with developmental disabilities and congenital anomalies and is also routinely applied in prenatal diagnosis. The cur...
Autism spectrum disorder (ASD) is characterized by high heritability estimates and recurrence rates; its genetic underpinnings are very heterogeneous and include variable combinations of common and ra...
The aim of this study was to evaluate both diagnostic yield and clinical impact of aCGH in 329 ASD patients of Italian descent....
Pathogenic/likely pathogenic CNVs were identified in 50/329 (15.2%) patients, whereas 89/329 (27.1%) carry variants of uncertain significance. The 10 most enriched gene sets identified by Gene Ontolog...
This study confirms the satisfactory diagnostic yield of aCGH, underscoring its potential for better, more in-depth care of children with autism when genetic results are analyzed also with a focus on ...
Azoospermia consists of a significant proportion of infertility aetiology in males. Although known genetic abnormalities may explain roughly the third of infertility cases, the exact aetiology is stil...
This study was performed to assess the optimal resolution for prenatal testing by array comparative genomic hybridization (aCGH), aiming to balance between maximum diagnostic yield and minimal detecti...
This was a prospective study using data of 2,336 fetuses that underwent invasive prenatal diagnosis, and the samples were analyzed by aCGH. In total, six different aCGH platforms were studied; four di...
The diagnostic yield of copy number variants increased with increasing level of analysis. The detection rates of clinically significant chromosomal abnormalities were almost the same across our target...
It appears that the targeted array platform with 0.5 Mb backbone resolution and 0.05 Mb on targeted gene-rich regions is optimal for routine chromosomal microarray analysis use in prenatal diagnosis. ...